Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


A role of menopause as a cardiovascular risk factor is reviewed. Menopause influence on the cardiovascular system may be mediated by body fat re-allocation, metabolic, hemodynamic and pro-inflammatory changes. Besides, estrogen deprivation has a direct effect on the arterial wall. Lifestyle modification, lipid-lowering and antihypertensive treatment should be considered for cardiovascular risk reduction in postmenopausal women.

About the Authors

D. A. Anichkov
Russian State Medical University, Moscow
Russian Federation
Therapy Department named after Nesterov

N. A. Shostak
Russian State Medical University, Moscow
Russian Federation
Therapy Department named after Nesterov

A. D. Zhuravleva
Hospital N1 named after Pirogov, Moscow
Russian Federation
Gynecology department


1. Gordon T, Kannel WB, Hjortland MC. Menopause and coronary heart disease: the Framingham study. Ann Intern Med 1978;89:157–61.

2. Witteman JC, Grobbee DE, Kok FJ, et al. Increased risk of atherosclerosis in women after the menopause. BMJ 1989;298:642–4.

3. Edmunds E, Lip GY. Cardiovascular risk in women: the cardiologist's perspective. QJM. 2000;93(3):135-45.

4. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999;353:571–80.

5. Prior JC. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev 1998;19(4):397–428.

6. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002;77:1207–18.

7. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003;88:2404–11.

8. Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynecol Endocrinol 1997;11:341–55.

9. Faria AN, Ribeiro Filho FF, Gouveia Ferreira SR, Zanella MT. Impact of visceral fat on blood pressure and insulin Sensitivity in hypertensive obese women. Obes Res 2002;10:1203–6.

10. Brochu M, Starling RD, Tchernof A, et al. Visceral adipose tissue is an independent correlate of glucose disposal in older obese post￾menopausal women. J Clin Endocrinol Metab 2000;85:2378–84.

11. Rendell M, Hulthen UL, Tornquist C, et al. Relationship between abdominal fat compartments and glucose and lipid metabolism in early postmenopausal women. J Clin Endocrinol Metab 2001;86:744–9.

12. Hernandez-Ono A, Monter-Carreola G, Zamora-Gonzalez J, et al. Association of visceral fat with coronary risk factors in population￾based sample of postmenopausal women. Int J obes Relat Metab Disord 2001;26:33–9.

13. Van Pelt RE, Evans EM, Schechtman KB, et al. Waist circumference vs body mass index for prediction of disease risk in postmenopausal women. Int J Obes Relat Metab Disord 2001;25:1183–8.

14. Lovergrove JA, Silva KDRR, Wright JW, Williams CM. Adiposity, insulin and lipid metabolism in post-menopausal women. Int J Obes Relat Metab Disord 2002;26:475–86.

15. Kuh D, Langenberg C, Hardy R, et al. Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy: a prospective British birth cohort study. BJOG 2005;112(4):476–85.

16. LaRosa JC. Evidence-based management of dyslipidemias in women. Curr Atheroscler Rep 2003;5:379–85.

17. Effects of estrogen or estrogen/progestin regimens on heart dis￾eases risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199–208.

18. Randomized comparison of oestrogen versus oestrogen plus progesterone hormone replacement therapy in women with hysterectomy. Medical Research Council's General Practice Research Framework. BMJ 1996;312:473–8.

19. Shakir YA, Samsioe G, Nyberg P, et al. Cardiovascular risk factors in middle-aged women and the association with use of hormone therapy: results from a population-based study of Swedish women. The Women's Health in the Lund Area (WHILA) Study. Climacteric 2004;7(3):274–83.

20. Nilsson PM, Lind L, Pollare T., et al. Differences in insulin sensitivity and risk marker due to gender and age in hypertensives. J Hum Hypertens 2000;14:51–6.

21. Kim HS, Abbasi F, Lamendola C, et al. Effect of insulin resistance on postprandial elevations of remnant lipoprotein concentrations in postmenopausal women. Am J Clin Nutr 2001;74:592–5. 22. Feldstein CA, Akopian M, Renauld A, et al. Insulin resistance and hypertension in postmenopausal women. J Hum Hypertens 2002;16(Suppl 1):S145–50.

22. Toth MJ, Sites CK, Eltabbakh GH, Poehlman ET. Effect of menopausal status on insulin-stimulated glucose disposal: comparison of middle-aged premenopausal and early postmenopausal women. Diabetes Care 2000;23:801–6. 24. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998;158:617–21.

23. Bolego C, Poli A, Paoletti R. Cardiovascular risk in diabetic women. Curr Atheroscler Rep 2003;5:79–81.

24. Howard BV, Cowan LD, Go O, et al. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. Diabetes Care 1998;21:1258–65.

25. Barrett-Connor EL, Cohn B, Wingard D, et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? JAMA 1991;265:627–631.

26. Anichkov DA, Maksina AG, Shostak NA. Relationships between erythrocyte membrane properties and components of metabolic syndrome in women. Med Sci Monit 2005;11(4):CR203–210.

27. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 2002;1:1.

28. Wilson PW, Kannell WB, Silbershatz H, D’Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999;159:1104–9.

29. Staessen J, Bulpit CJ, Fagard R, et al. The influence of menopause on blood pressure. J Hum Hypertens 1989;3:427–33.

30. Staessen J, Ginocchio G, Thijs L, Fagard R. Conventional and ambulatory blood pressure and menopause in a prospective population study. J Hum Hypertens 1997;11:507–14.

31. Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women: baseline data from Women’s Health Initiative. Hypertension 2000:36:780–9.

32. Schillaci G, Verdecchia P, Borgioni C, et al. Early cardiac changes after menopause. Hypertension 1998:32:764–9.

33. Sherwood A, Thurston R, Steffen P, et al. Blunted nighttime blood pressure dipping in postmenopausal women. Am J Hypertens 2001;14:749–54.

34. Rosental T, Oparil S. Hypertension in women. J Hum Hypertens 2000; 14: 691–704.

35. Kotchen JM, Kotchen TA. Impact of female hormones on blood pressure: review of potential mechanisms and clinical studies. Curr Hypertens Rep 2003;5:505–12.

36. Nickenig G, Baumer AT, Grohe C, et al. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 1998;97:2197–201.

37. Vilecco AS, de Aloyso D, Radi D, et al. Plasma catecholamines in pre- and postmenopausal women with mild to moderate essential hypertension. J Hum Hypertens 1997;11:152–62.

38. Mercuro G, Podda A, Pitzalis L, et al. Evidence of a role of endogenous estrogen in the modulation of autonomic nervous system. Am J Cardiol 2000;85(6):787–9.

39. Vongpatanasin W, Tuncel M, Mansour Y, et al. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation 2001;103:2903–8.

40. Barbagallo M, Dominguez LJ, Licata G, Resnick LM. Effects of aging on serum ionized and cytosolic free calcium: relation to hyperten￾sion and diabetes. Hypertension 1999;34:902–6.

41. Mercuro G, Zoncu S, Cherchi A, Rosano GM. Can menopause be considered an independent risk factor for cardiovascular disease? Ital Heart J 2001;2(10):719–27.

42. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among appar￾ently healthy women. Circulation 1998;98(8):731–3.

43. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557–65.

44. Margolis KL, Manson JE, Greenland P, et al. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med 2005;165(5):500–8.

45. Pfeilschifter J, Koditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002;23:90–119.

46. Cantatore F, Loverro G, Ingrosso A, et al. Effect of oestrogen replacement on bone metabolism and cytokines in surgical menopause. Clin Rheumatol 1995;14(2):157–60.

47. Cioffi M, Esposito K, Vietri M, et al. Cytokine pattern in postmenopause. Maturitas 2002;41(3):187–92.

48. Luyer MDP, Khosla S, Owen WG, Miller VM. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab 2001;86:3629–34.

49. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003;88(6):2470–8.

50. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33.

51. Gabriel SR, Carmona L, Roque M, et al. Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2005;(2):CD002229.

52. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799–804.

53. Sciacqua A, Candigliota M, Ceravolo R, et al. Weight loss in combination with physical activity improves endothelial dysfunction in human obesity. Diabetes Care 2003;26:1673–8.

54. Mostaghel E, Waters D. Women do benefit from lipid lowering: latest clinical trial data. Cardiol Rev 2003;11:4–12.

55. McCarey DW, Sattar N, McInnes IB. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? Arthritis Res Ther 2005;7(2):55–61.

56. Fisman EZ, Tenenbaum A, Pines A. Systemic hypertension in postmenopausal women: a clinical approach. Curr Hypertens Rep 2002;4:464–70.

57. Esler M, Lux A, Jennings G, et al. Rilmenidine sympatholytic activity preserves mental stress, orthostatic sympathetic responses and adrenaline secretion. J Hypertens 2004;22:1529–34.

58. Penicaud L, Berthault MF, Morin J, et al. Rilmenidine normalizes fructose-induced insulin resistance and hypertension in rats. J Hypertens Suppl 1998;16:S45–9.

59. Remkova A, Kratochvil'ova H. Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension. J Hum Hypertens 2002;16(8):549–55.

60. Piletz JE, Halbreich U. Imidazoline and alpha(2a)-adrenoceptor binding sites in postmenopausal women before and after estrogen replacement therapy. Biol Psychiatry 2000;48(9):932–9.

61. Anichkov DA, Shostak NA, Schastnaya OV. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin 2005;21(1):113–9.

For citation:

Anichkov D.A., Shostak N.A., Zhuravleva A.D. MENOPAUSE AND CARDIOVASCULAR RISK. Rational Pharmacotherapy in Cardiology. 2005;1(1):37-42. (In Russ.)

Views: 434

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)